Insider Stock Trading History of Patterson Matthew R


The following table details the trading activities (stock purchases, stock sales, and stock option exercises) reported to the Securities and Exchange Commission (SEC) by insider Patterson Matthew R since year 2005. The trader's CIK number is 1401018. At the time of this reporting, Patterson Matthew R is the President & CEO of Audentes Therapeutics, Inc. . (stock ticker symbol BOLD). See this page for all insider trading activities at Audentes Therapeutics, Inc. .

Note that in the past Patterson Matthew R also reported insider trading activities as an insider of the following companies:
Stock purchases, sales, and option exercises reported by insider Patterson Matthew R since 2005.
  Trade Date   Symbol Company Name (Issuer) Trade Type     Shares       Price ($)   Value ($)
2017-10-02 BOLD Audentes Therapeutics, Inc. Option Ex 10,000 .78 7,800
2017-10-02 BOLD Audentes Therapeutics, Inc. Sale 25,000 27.92 698,075
2017-09-15 BOLD Audentes Therapeutics, Inc. Option Ex 1,542 .78 1,202
2017-09-15 BOLD Audentes Therapeutics, Inc. Sale 1,542 25.00 38,551
2017-09-18 BOLD Audentes Therapeutics, Inc. Option Ex 8,458 .78 6,597
2017-09-18 BOLD Audentes Therapeutics, Inc. Sale 8,458 25.07 212,008
2017-07-13 BOLD Audentes Therapeutics, Inc. Sale 12,150 20.00 243,048
2017-07-12 BOLD Audentes Therapeutics, Inc. Sale 2,850 20.00 57,008
2008-12-02 FOLD Amicus Therapeutics Inc Option Ex 20,098 .64 12,822
2008-10-30 FOLD Amicus Therapeutics Inc Sale 361 10.00 3,610
2008-10-31 FOLD Amicus Therapeutics Inc Sale 1,939 10.00 19,390
2008-10-22 FOLD Amicus Therapeutics Inc Sale 3,100 10.40 32,246
2008-10-23 FOLD Amicus Therapeutics Inc Sale 100 10.10 1,010
2008-10-20 FOLD Amicus Therapeutics Inc Sale 2,000 11.12 22,242
2008-10-21 FOLD Amicus Therapeutics Inc Sale 2,500 10.51 26,262
2008-10-20 FOLD Amicus Therapeutics Inc Sale 2,000 11.12 22,242
2008-10-21 FOLD Amicus Therapeutics Inc Sale 2,500 10.51 26,262
2008-08-20 FOLD Amicus Therapeutics Inc Sale 2,000 13.54 27,070
2008-08-18 FOLD Amicus Therapeutics Inc Sale 3,500 15.53 54,358
2008-08-19 FOLD Amicus Therapeutics Inc Sale 4,500 14.10 63,468
2008-06-20 FOLD Amicus Therapeutics Inc Sale 1,400 11.38 15,932
2008-06-18 FOLD Amicus Therapeutics Inc Sale 1,500 11.01 16,512
2008-06-19 FOLD Amicus Therapeutics Inc Sale 400 11.05 4,421
2008-06-17 FOLD Amicus Therapeutics Inc Sale 1,800 11.08 19,945
2008-06-16 FOLD Amicus Therapeutics Inc Sale 4,900 11.18 54,801
2008-04-14 FOLD Amicus Therapeutics Inc Sale 5,500 10.47 57,612
2008-04-14 FOLD Amicus Therapeutics Inc Sale 500 10.75 5,375
2008-04-15 FOLD Amicus Therapeutics Inc Sale 3,422 10.17 34,808
2008-04-16 FOLD Amicus Therapeutics Inc Sale 578 10.00 5,780
2008-02-21 FOLD Amicus Therapeutics Inc Option Ex 12,083 .64 7,708
2007-08-15 FOLD Amicus Therapeutics Inc Option Ex 32,366 .64 20,649

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Patterson Matthew R (President & CEO of Audentes Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.